<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940722-0-00037</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments by August 15, 1994 , in order for written comments to be considered for discussion at the September 8 and 9, 1994, advisory committee meeting. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 343</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 94N&hyph;0255]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Over-the-Counter Marketing of Internal Analgesic, Antipyretic, and Antirheumatic Drug Products; Background Document for Advisory Committee Meeting; Availability; Establishment of a Public Docket and Request for Comments  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Availability of background document; establishment of a public docket and request for comments. <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration is announcing the availability of a background document for the joint meeting of the Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee on effectiveness data requirements and labeling for over-the-counter (OTC) marketing of internal analgesic, antipyretic and antirheumatic drug products scheduled for September 8 and 9, 1994. The background information is being made available to ensure that all interested parties are aware of the issues that are the subject of the committee discussion. FDA is also announcing that it is establishing a public docket for comments, views, and other information submitted to the agency on these subjects from interested persons. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments by August 15, 1994 , in order for written comments to be considered for discussion at the September 8 and 9, 1994, advisory committee meeting. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments or relevant data and requests for single copies of the background document to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. Comments and requests should be identified with the docket number found in the brackets in the heading of this document. Send two self-addressed adhesive labels to assist the branch in processing your requests. Three copies of written comments should be submitted, except that individuals may submit one copy. The background document and received comments are available for public examination at the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Lee L. Zwanziger, Center for Drug Evaluation and Research (HFD&hyph;9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;4695. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  of July 11, 1994 (59 FR 35375), FDA announced that a forthcoming joint meeting of the Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee on effectiveness data requirements and labeling for over-the-counter (OTC) marketing of internal analgesic, antipyretic and antirheumatic drug products will be held on September 8 and 9, 1994. FDA is holding this meeting to discuss: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1) Data requirements to support specific types of indications for OTC analgesic drug products; <!-- PJG 0012 frnewline --> (2) Recommendations for labeling indications for OTC analgesics; and <!-- PJG 0012 frnewline --> (3) The current state of scientific knowledge in the areas of pain receptors, mechanism(s) of pain perception, and the basis for response to analgesic drug classes. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The purpose of this meeting is to address specific topics and questions contained in the background document that could result in future rulemaking. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> FDA has established public docket No. 94N&hyph;0255 to enable interested persons to submit comments or other relevant data on the background document. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: July 15, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;17811 Filed 7&hyph;21&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            